Named Bioactive Compounds · Compound
Evodiamine
Moderate Evidencealkaloid3 PubMed Studies
Hermetica Superfood Encyclopedia
Evodiamine is a quinolone alkaloid extracted from the fruit of Evodia rutaecarpa (Wu-Zhu-Yu) that exerts its primary effects by acting as a TRPV1 (vanilloid receptor 1) agonist, a mechanism shared with capsaicin. Preclinical research highlights its anti-tumor and anti-inflammatory activities, though human clinical trials remain largely absent.
Evodiamine is a naturally occurring indole alkaloid extracted from the dried, unripe fruits of Tetradium ruticarpum (Evodia rutaecarpa), a plant in the Rutaceae family traditionally used in Chinese medicine. The compound appears as yellow flaky crystals or crystalline powder and is extracted through boiling under alcoholic liquor from the fruit, which contains volatile oils and multiple alkaloids.
The available research on evodiamine consists primarily of laboratory and animal studies demonstrating anti-tumor, anti-inflammatory, and weight loss effects, with no human clinical trials, RCTs, or meta-analyses provided in the research dossier. The compound is noted as a 'potential candidate anti-cancer agent' based on preclinical evidence only, with human bioavailability documented at an extremely low 0.1% following oral administration.
No clinically studied human dosage ranges are available in the research. Animal studies reference 500 mg/kg in rats, but this cannot be extrapolated to human dosing. Standardization parameters and clinical dosing recommendations have not been established. Consult a healthcare provider before starting any new supplement.
Evodiamine is a bioactive indoloquinazoline alkaloid (molecular formula C₁₉H₁₇N₃O, MW 303.36 g/mol) isolated primarily from the fruit of Evodia rutaecarpa (Wu-Zhu-Yu) and related Tetradium species. It is not a nutrient per se and does not possess a conventional nutritional profile (no significant macronutrients, vitamins, minerals, fiber, or protein content). Key details: • Concentration in source material: Typically 0.1–0.8% w/w in dried Evodia rutaecarpa fruit, varying by cultivar, harvest time, and processing method; often co-occurs with rutaecarpine (a structurally related alkaloid) at comparable levels. • Bioactive compound class: Quinazolinocarboline (indoloquinazoline) alkaloid; acts as a TRPV1 (vanilloid receptor) agonist, thermogenic agent, and modulator of multiple signaling pathways (NF-κB, PI3K/Akt, MAPK, topoisomerase I/II inhibition). • Bioavailability: Oral bioavailability in rodent models is notably low, estimated at approximately 0.1–1.6% due to extensive first-pass hepatic metabolism (primarily CYP1A2- and CYP3A4-mediated oxidation and glucuronidation). Plasma half-life in rats is approximately 0.3–0.8 hours. P-glycoprotein efflux further limits intestinal absorption. Co-administration with piperine or lipid-based delivery systems has been explored to enhance bioavailability. • Typical supplemental doses studied: 20–100 mg/day in human supplement formulations (limited clinical data); rodent studies commonly use 10–80 mg/kg body weight orally. • Other co-occurring bioactives in Evodia fruit: Rutaecarpine (0.1–0.5%), dehydroevodiamine (0.05–0.3%), limonin, synephrine, and various flavonoids, which may contribute to synergistic effects. • Solubility: Poorly water-soluble; soluble in organic solvents (DMSO, ethanol, chloroform). This limits formulation options and contributes to low oral bioavailability. • No caloric value, no appreciable carbohydrate, fat, or protein contribution at pharmacologically relevant doses.
Evodiamine binds and activates the transient receptor potential vanilloid 1 (TRPV1) channel, triggering calcium influx that modulates pain signaling and inflammatory cascades, similar to capsaicin. In cancer cell studies, it induces apoptosis by activating caspase-3 and caspase-9 pathways, downregulating Bcl-2, and inhibiting NF-κB transcriptional activity, which collectively suppress tumor cell proliferation. Additionally, evodiamine has been shown to inhibit topoisomerase I and II activity, interfering with DNA replication in rapidly dividing cells.
The vast majority of evidence for evodiamine comes from in vitro cell line studies and rodent models, with no large-scale randomized controlled trials in humans published to date. In cell culture experiments, evodiamine demonstrated antiproliferative effects against HeLa (cervical), HCT116 (colon), A549 (lung), melanoma, HL-60 (leukemia), LNCaP (prostate), and MCF-7 (breast) cancer lines, typically at concentrations of 1–50 µM. Animal studies using oral doses of 10–50 mg/kg in mice have shown reduced tumor volume and anti-inflammatory outcomes, but pharmacokinetic challenges including low oral bioavailability limit direct translation to human dosing. The current evidence base is preclinical only, and no therapeutic claims can be substantiated without human trial data.
Human safety data for evodiamine is limited; at high doses in animal models, hepatotoxic effects have been observed, mirroring concerns already documented for the parent herb Evodia rutaecarpa. Because evodiamine activates TRPV1 similarly to capsaicin, it may cause gastrointestinal irritation, including nausea or stomach discomfort, particularly on an empty stomach. Potential drug interactions exist with anticoagulants and cytochrome P450 substrates, as Evodia alkaloids have demonstrated CYP1A2 and CYP3A4 inhibitory activity in vitro. Evodiamine is contraindicated during pregnancy due to documented uterotonic effects of Evodia rutaecarpa preparations in traditional use and animal studies.
